Orchid Pharma Limited (ORCHPHARMA.NS)
INR 1794.0
(0.9%)
INR 1794.0
(0.9%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.35 Billion INR | -59.2% |
| 2022 | 3.31 Billion INR | 23.66% |
| 2021 | 2.67 Billion INR | -40.82% |
| 2020 | 4.52 Billion INR | -19.71% |
| 2019 | 5.63 Billion INR | -82.54% |
| 2018 | 32.29 Billion INR | 0.87% |
| 2017 | 32.01 Billion INR | 3.08% |
| 2016 | 31.06 Billion INR | -3.37% |
| 2015 | 32.14 Billion INR | 2.36% |
| 2014 | 31.4 Billion INR | -1.98% |
| 2013 | 32.04 Billion INR | 0.0% |
| 2011 | 20.05 Billion INR | 50.55% |
| 2010 | 13.31 Billion INR | 28.58% |
| 2009 | 10.35 Billion INR | -43.21% |
| 2008 | 18.24 Billion INR | 53.35% |
| 2007 | 11.89 Billion INR | 49.34% |
| 2006 | 7.96 Billion INR | -23.77% |
| 2005 | 10.44 Billion INR | 3.96% |
| 2004 | 10.05 Billion INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 1.35 Billion INR | -59.2% |
| 2023 Q2 | 1.47 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 1.35 Billion INR | 0.0% |
| 2022 Q2 | 3.39 Billion INR | 0.0% |
| 2022 Q4 | 3.31 Billion INR | 0.0% |
| 2022 FY | 3.31 Billion INR | 23.66% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 2.67 Billion INR | -40.82% |
| 2021 Q4 | 2.67 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 2.95 Billion INR | 0.0% |
| 2020 Q2 | 4.36 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 4.52 Billion INR | 0.0% |
| 2020 FY | 4.52 Billion INR | -19.71% |
| 2020 Q1 | - INR | -100.0% |
| 2019 FY | 5.63 Billion INR | -82.54% |
| 2019 Q4 | 5.63 Billion INR | 0.0% |
| 2019 Q1 | - INR | 0.0% |
| 2018 FY | 32.29 Billion INR | 0.87% |
| 2018 Q2 | 24.77 Billion INR | 0.0% |
| 2017 FY | 32.01 Billion INR | 3.08% |
| 2016 FY | 31.06 Billion INR | -3.37% |
| 2015 FY | 32.14 Billion INR | 2.36% |
| 2014 FY | 31.4 Billion INR | -1.98% |
| 2013 FY | 32.04 Billion INR | 0.0% |
| 2013 Q2 | 24.26 Billion INR | 0.0% |
| 2011 FY | 20.05 Billion INR | 50.55% |
| 2011 Q4 | 20.05 Billion INR | 0.0% |
| 2010 FY | 13.31 Billion INR | 28.58% |
| 2009 FY | 10.35 Billion INR | -43.21% |
| 2008 FY | 18.24 Billion INR | 53.35% |
| 2007 FY | 11.89 Billion INR | 49.34% |
| 2006 FY | 7.96 Billion INR | -23.77% |
| 2005 FY | 10.44 Billion INR | 3.96% |
| 2004 FY | 10.05 Billion INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Sigachi Industries Limited | 1.43 Billion INR | 5.502% |
| Ind-Swift Limited | 10.13 Billion INR | 86.669% |
| Bajaj HealthCare Limited | 3.32 Billion INR | 59.384% |
| Sakar Healthcare Limited | 793.51 Million INR | -70.356% |
| Aurobindo Pharma Limited | 66.47 Billion INR | 97.966% |
| Innova Captab Limited | 2.45 Billion INR | 44.848% |
| Divi's Laboratories Limited | 30 Million INR | -4406.02% |
| AstraZeneca Pharma India Limited | 45.98 Million INR | -2839.859% |
| Morepen Laboratories Limited | 289.99 Million INR | -366.153% |
| Mankind Pharma Limited | 2.07 Billion INR | 34.75% |
| Sequent Scientific Limited | 4.87 Billion INR | 72.282% |
| Wanbury Limited | 1.16 Billion INR | -16.05% |
| Laurus Labs Limited | 25.77 Billion INR | 94.755% |
| Nectar Lifesciences Limited | 6.35 Billion INR | 78.73% |
| Glenmark Life Sciences Limited | 171.48 Million INR | -688.317% |
| Alembic Limited | 91.5 Million INR | -1377.384% |
| Hikal Limited | 8.17 Billion INR | 83.466% |
| Alembic Pharmaceuticals Limited | 5.13 Billion INR | 73.657% |
| Neuland Laboratories Limited | 953.89 Million INR | -41.714% |
| J. B. Chemicals & Pharmaceuticals Limited | 3.77 Billion INR | 64.206% |
| Glenmark Pharmaceuticals Limited | 12.3 Billion INR | 89.018% |
| IOL Chemicals and Pharmaceuticals Limited | 327.6 Million INR | -312.639% |
| Themis Medicare Limited | 957.92 Million INR | -41.119% |
| RPG Life Sciences Limited | - INR | -Infinity% |
| Zydus Lifesciences Limited | 8.04 Billion INR | 83.191% |
| Lupin Limited | 29.21 Billion INR | 95.373% |
| Amrutanjan Health Care Limited | 17.28 Million INR | -7721.593% |
| Wockhardt Limited | 23.56 Billion INR | 94.262% |
| Vaishali Pharma Limited | 134.91 Million INR | -901.946% |
| Aarti Pharmalabs Limited | 2.85 Billion INR | 52.61% |
| Jagsonpal Pharmaceuticals Limited | 89.41 Million INR | -1411.918% |
| Jubilant Pharmova Limited | 36.64 Billion INR | 96.311% |
| FDC Limited | 205.18 Million INR | -558.823% |
| Dr. Reddy's Laboratories Limited | 20.02 Billion INR | 93.248% |
| Kilitch Drugs (India) Limited | 316.46 Million INR | -327.158% |
| Eris Lifesciences Limited | 27.81 Billion INR | 95.14% |
| Venus Remedies Limited | 413.3 Million INR | -227.076% |
| ZIM Laboratories Limited | 1.08 Billion INR | -24.219% |
| Bliss GVS Pharma Limited | 998.4 Million INR | -35.397% |
| Par Drugs and Chemicals Limited | - INR | -Infinity% |
| Caplin Point Laboratories Limited | 19.7 Million INR | -6761.959% |
| Shilpa Medicare Limited | 9.37 Billion INR | 85.579% |
| Albert David Limited | 33.24 Million INR | -3966.56% |
| Ajanta Pharma Limited | 352.8 Million INR | -283.165% |
| Hester Biosciences Limited | 2.44 Billion INR | 44.684% |
| Suven Pharmaceuticals Limited | 649.96 Million INR | -107.982% |
| Solara Active Pharma Sciences Limited | 10.11 Billion INR | 86.636% |
| Gufic Biosciences Limited | 3.32 Billion INR | 59.395% |
| Windlas Biotech Limited | 36.41 Million INR | -3612.733% |
| Procter & Gamble Health Limited | 95.6 Million INR | -1314.023% |
| Aarey Drugs & Pharmaceuticals Limited | 313.52 Million INR | -331.166% |
| Mangalam Drugs & Organics Limited | 984.92 Million INR | -37.25% |
| Granules India Limited | 13.15 Billion INR | 89.721% |
| Aarti Drugs Limited | 5.64 Billion INR | 76.043% |
| Bal Pharma Limited | 1.39 Billion INR | 3.199% |
| Alkem Laboratories Limited | 14.18 Billion INR | 90.47% |
| Sun Pharmaceutical Industries Limited | 32.73 Billion INR | 95.871% |
| Lincoln Pharmaceuticals Limited | 10.66 Million INR | -12571.597% |
| Medicamen Biotech Limited | 308.17 Million INR | -338.653% |
| Unichem Laboratories Limited | 2.47 Billion INR | 45.385% |
| Bafna Pharmaceuticals Limited | 243.89 Million INR | -454.262% |
| Biofil Chemicals and Pharmaceuticals Limited | 4.38 Million INR | -30699.863% |
| Valiant Laboratories Limited | 767.08 Million INR | -76.227% |
| Medico Remedies Limited | 80.5 Million INR | -1579.179% |
| Ind-Swift Laboratories Limited | 166.21 Million INR | -713.283% |
| Ipca Laboratories Limited | 14.38 Billion INR | 90.602% |
| Brooks Laboratories Limited | 56.41 Million INR | -2296.012% |
| Syncom Formulations (India) Limited | 724.86 Million INR | -86.49% |
| Piramal Enterprises Limited | 535.85 Billion INR | 99.748% |
| Torrent Pharmaceuticals Limited | 40.22 Billion INR | 96.639% |
| NATCO Pharma Limited | 3.71 Billion INR | 63.583% |
| Suven Life Sciences Limited | 7.09 Million INR | -18947.569% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 30.114% |
| Strides Pharma Science Limited | 25.16 Billion INR | 94.629% |
| Indoco Remedies Limited | 6.71 Billion INR | 79.883% |
| Alpa Laboratories Limited | 52.46 Million INR | -2476.586% |
| Lasa Supergenerics Limited | 220.76 Million INR | -512.336% |
| Sun Pharma Advanced Research Company Limited | 611.5 Million INR | -121.064% |